M4MM

Alabama Seeks to Expand Medical Cannabis Licensing

LOS ANGELES- In an effort to resolve ongoing legal disputes surrounding its medical cannabis licensing process, Alabama has introduced a bill proposing an increase in the number of available licenses. Filed on Tuesday, the legislation ...

Oregon Reinstates Criminal Penalties for Drug Possession

LOS ANGELES- In a landmark reversal, Oregon Governor Tina Kotek has endorsed House Bill 4002, reintroducing criminal penalties for possession of controlled substances such as fentanyl, heroin, and methamphetamine. This action marks a departure from ...

Alberta Leads in Psychedelic-Assisted Therapy Coverage

NEW YORK- Alberta Blue Cross's recent endorsement of insurance coverage for Psychedelic-Assisted Therapy signifies a pioneering move in Canadian healthcare, positioning Alberta as the first province to officially support and regulate such treatments. This development ...

Ontario Anticipates Record Cannabis Revenue

LOS ANGELES- In a landmark financial forecast, Ontario expects to garner over CA$379 million from its share of the federal cannabis duty for the fiscal year April 2024 to March 2025, marking a significant 22.2% ...

Delaware Expands Medical Cannabis Program Access

NEW YORK- Delaware lawmakers have passed a significant bill aimed at broadening access to the state's medical cannabis program. On Thursday, the Delaware Senate approved a proposal that grants healthcare providers the discretion to certify ...

Maryland Awards Social Equity Cannabis Licenses

LOS ANGELES- In a significant move by the Maryland Cannabis Administration, 174 social equity cannabis licenses were awarded through a lottery system, showcasing the state's commitment to diversity and inclusion within the burgeoning cannabis industry. ...

Organigram Announces Investment in Open Book Extracts

NEW YORK- Organigram Holdings, a Canadian cannabis company, announced a $2 million investment in North Carolina-based Open Book Extracts. This move signifies Organigram's entry into the U.S. cannabis market, facilitated by an investment from British ...

Algernon Pharmaceuticals Advances Research Program

LOS ANGELES – In a significant move that underscores its commitment to innovative medical research, Algernon Pharmaceuticals Inc. announced its decision to prioritize its AP-188 ("N,N-Dimethyltryptamine" or "DMT") stroke research program. This announcement follows the ...

Subscribe To Our Newsletter